Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells Publisher Pubmed



Keshtvarz M1 ; Salimian J2 ; Yaseri M3 ; Bathaie SZ4 ; Rezaie E5 ; Aliramezani A1 ; Norouzbabaei Z6 ; Amani J5 ; Douraghi M1, 7
Authors

Source: Immunotherapy Published:2017


Abstract

Aim: AFn14R can serve as an ideal target for cancer immunotherapy. Here, a combined bioinformatic and experimental approach was applied to characterize an immunotoxin consisting of single-chain variable fragment antibody that targets Fn14 and a toxin fragment (PE38). Methods & Results: Flow cytometry results showed that the rate of PE38-P4A8 binding to Fn14 was approximately 60 and 40% in HT-29 and A549 cells, respectively. Moreover, 1 ng/l of immunotoxin was able to lyse approximately 53 and 41% of HT-29 and A549, respectively. PE38-P4A8 showed stability in mouse serum (∼90%) after 3-h incubation. Most importantly, using bioinformatics for determining the structure and function of fusion proteins can be very helpful in designing of experiments. Conclusion: Coupled with bioinformatics, experimental approaches revealed that PE38-P4A8 could be used as a promising therapeutic agent for cancer cells expressing Fn14. © 2017 Future Medicine Ltd.
Related Docs
View other Related Docs
1. A Novel Shiga Based Immunotoxin Against Fn-14 Receptor on Colorectal and Lung Cancer, International Immunopharmacology (2022)
2. Advances in Immunotoxin Engineering: Precision Therapeutic Strategies in Modern Oncology, Medical Oncology (2024)
3. A Review on the Types of Immunotoxins and Their Use in Cancer Treatment: Review Article, Tehran University Medical Journal (2018)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (2)
Mohammad Reza Fazeli (2)
Other Related Docs
4. Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (Cls) and Recently Developed Countering Strategies, Current Molecular Medicine (2018)
5. Cytotoxic and Apoptotic Properties of a Novel Nano-Toxin Formulation Based on Biologically Synthesized Silver Nanoparticle Loaded With Recombinant Truncated Pseudomonas Exotoxin A, Journal of Cellular Physiology (2020)
6. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
7. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
8. Epitope-Based Immunoinformatics Study of a Novel Pilq380–706-Pila Fusion Protein From Pseudomonas Aeruginosa, Gene Reports (2019)
9. Unraveling Potential Candidate Targets Associated With Expression of P16ink4a or P16 Truncated Fragment by Comparative Proteomics Analysis, Current Proteomics (2022)
10. A Simplified Process for Purification and Refolding of Recombinant Human Interferon-Α2b, Iranian Biomedical Journal (2022)
11. Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain, Human Antibodies (2020)
12. Design and Evaluation of Scfv-Rtx-A As a Novel Immunotoxin for Breast Cancer Treatment: An in Silico Approach, Journal of Immunoassay and Immunochemistry (2021)
13. The Importance of the Non-Active Site and Non-Periodical Structure Located Histidine Residue Respect to the Structure and Function of Exo-Inulinase, International Journal of Biological Macromolecules (2017)
14. Synthesis of the Scfv Fragment of Anti-Frizzled-7 Antibody and Evaluation of Its Effects on Triple-Negative Breast Cancer in Vitro Study, Clinical and Translational Oncology (2024)
15. Contribution of Fc Fragment of Monoclonal Antibodies to Tetanus Toxin Neutralization, Neurotoxicity Research (2020)
16. Solubilization of Human Interferon Β-1B Inclusion Body Proteins by Organic Solvents, Advanced Pharmaceutical Bulletin (2020)
17. An Update to Experimental and Clinical Aspects of Tumor-Associated Macrophages in Cancer Development: Hopes and Pitfalls, Clinical and Experimental Medicine (2024)
18. Development and Evaluation of a Novel E7 Multi-Epitopic Vaccine for Human Papillomavirus Type 16: Design, Expression, Purification, and Immunological Characterization, BMC Infectious Diseases (2025)
19. Computational Structure-Based Design of Antiviral Peptides As Potential Protein–Protein Interaction Inhibitors of Rabies Virus Phosphoprotein and Human Lc8, Heliyon (2025)
20. Immunoinformatics Approach: Developing a Multi-Epitope Vaccine With Novel Carriers Targeting Monkeypox Virus, FASEB Journal (2024)